Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-24
2006-10-24
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S802000, C530S380000, C530S384000
Reexamination Certificate
active
07125841
ABSTRACT:
The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.
REFERENCES:
patent: 4994371 (1991-02-01), Davie et al.
patent: 5171569 (1992-12-01), Anson et al.
patent: 5521070 (1996-05-01), Meulien
patent: 5614500 (1997-03-01), Zimmermann
patent: 5639857 (1997-06-01), Zimmermann
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5814716 (1998-09-01), Jallat et al.
patent: 5935935 (1999-08-01), Connelly et al.
patent: 6034222 (2000-03-01), Fischer et al.
patent: 6063909 (2000-05-01), Huang et al.
patent: 6093392 (2000-07-01), High et al.
patent: 0195592 (1986-09-01), None
patent: 0430930 (1991-06-01), None
patent: WO 84/00560 (1984-02-01), None
patent: WO 98/33907 (1998-08-01), None
patent: WO 99/03496 (1999-01-01), None
patent: WO 02/40544 (2002-05-01), None
Chang et al. Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity. (May 15, 1998) J. Biol. Chem. vol. 273, No. 20, pp. 12089-12094.
Nishimura et al. Characterization of Factor IX Fukuoka with Substitution of Asn-92 by His in the 2ndEpidermal Growth Factor-Like Domain. (1991) Thromb. Haemost. vol. 65, No. 6, p. 712.
Andersson, “Purification and characterization of human factor IX,” Thrombosis Research 7:451-459, 1975.
Austen et al., “A laboratory manual of blood coagulation,” Blackwell Scientific Publishing, 1975.
Bajaj et al., “Human factor IX and factor IXa,” Meth. Enzymol. 222:96-128, 1993.
Banner et al., “The crystal structure of the complex of blood coagulation factor Vlla with soluble tissue factor,” Nature 380:41-46, 1996.
Barrow et al., “Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator,” J. Biol. Chem. 269:26796-26800, 1994.
Bessos et al., “Immunopurification of human coagulation factor IX using monoclonal antibodies,” Thromb. Haemostas. 56:86-89, 1986.
Better et al., “Escherichia colisecretion of an active chimeric antibody fragment,” Science 240:1041-1043. 1988.
Bitter et al., “Secretion of foreign proteins fromSaccharomyces cerevisiaedirected by α-factor gene fusions,” Proc. Natl. Acad. Sci. USA 81:5330-5334, 1984.
Brandstetter et al., “X-ray structure of clotting factor IXa: Active site and module structure related to Xase Activity and hemophilia B,” Proc. Natl. Acad. Sci. USA 92:9796-9800, 1995.
Busby et al., “Expression of active human factor IX in transfected cells,” Nature 316:271-273, 1985.
Chang et al., “Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity,” J. Biol. Chem. 273:12089-12094, 1998.
Cote et al., “Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A),” J. Biol. Chem. 269:11374-11380, 1994.
Engelhard et al., “The insect tracheal system: A conduit for the systemic spread ofAutographa californicaM nuclear polyhedrosis virus,” Proc. Natl. Acad. Sci. USA 91:3224-3227, 1994.
Evans et al., “Molecular cloning of a cDNA encoding canine factor IX,” Blood 74:207-212, 1989.
Fay et al., “Molecular for the factor Vllla-dependent decay of the intrinsic factor Xase,” J. Biol. Chem. 271:6027-6032, 1996.
Galeffi et al., The propeptide region of clotting factor IX is a signal for a vitamin K dependent carboxylase: evidence from protein engineering of amino acid -4, Nucl. Acids. Res. 15:9505-9513, 1987.
Hamaguchi et al., Expression and characterization of human factor IX,J. Biol. Chem. 266:15213-15220, 1991.
Hathaway et al., “Laboratory measurement of hemostasis and thrombosis,” In: Disorders of Hemostastis and Thrombosis: A Clinical Guide, pp. 21-29, 1993.
Hirsh et al., “Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety,” Chest 108(4 Suppl): 258S-275S, 1995.
Hoffman et al., “Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation,” Blood 86:1794-1801, 1995.
Holmer et al., “The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xlla and kallikrein by antithrombin,” Biochem. J. 193:395-400, 1981.
Hopfner et al., “Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding,” Structure 7:989-996, 1999.
Huang et al., “Molecular defect in factor IXHilo, a hemophilia Bmvariant: Arg—Gln at the carboxyterminal cleavage site of the activation peptide,” Blood 73:718-721, 1989.
Jordan et al., “The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin,” J. Biol. Chem. 255:10081-10090, 1980.
Kaufman et al., “Expression, purification, and characterization of recombinant γ-carboxylated factor IX synthesized in Chinese hamster ovary cells,” J. Biol. Chem. 261:9622-9628, 1986.
Kung et al., “Human factor IX corrects the bleeding diathesis of mice with hemophilia B,” Blood 91:784-790, 1998.
Kurjan et al., “Structure of a yeast pheromone gene (MFα): A putative α-factor precursor contains four tandem copies of mature α-factor,” Cell 30:933-943, 1982.
Larson et al., “Structural integrity of the γ-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor Vllla,” J. Biol. Chem. 271:3869-3876, 1996.
Lawson et al., “A model for the tissue factor pathway to thrombin,” J. Biol. Chem. 269:23357-23366, 1994.
Liebman et al., “Immunoaffinity purification of human factor IX using conformation-specific polyclonal and monoclonal antibodies,” Blood 62, suppl. 1, 288a, Abstract π 1055, 1983.
Liebman et al., “Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex,” Proc. Natl. Acad. Sci. USA 82:3879-3883, 1985.
Lin et al., “A coagulation factor IX-deficient mouse model for human hemophilia B,” Blood 90:3962-3966, 1997.
Mathur et al., “Interaction of factor IXa with factor Vllla,” J. Biol. Chem. 272:23418-23426, 1997.
Mauray et al., “Mechanism of factor IXa inhibition of antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan,” Biochim. Biophys. Acta. 1387:184-194, 1998.
McNeely et al., The anticoagulant mechanism of action of heparin in contact-activated plasma: inhibition of factor X activation, Blood 65:1226-1231, 1985.
Meulien et al., “Increased biological activity of a recombinant factor IX variant carrying alanine at position+1,” Prot. Engineer. 3:629-633, 1990.
Neels et al., “Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein,” Blood 96:3459-3465, 2000.
Noyes et al., “Identfication of the molecular defect in factor IXChapel Hill: Substitution of histidine for arginine at position 145,” Proc. Natl. Acad. Sci. USA 80:4200-4202, 1983.
Olson et al., “Quantitative characterization of the thrombin-heparin interaction” J. Biol. Chem., 266:6342-6352, 1991.
Pieters et al., “Inhibition of factor IXaand Xaby antithrombin lll/heparin during factor X activation,” J. Biol. Chem. 263:15313-15318, 1988.
Pieters et al., “Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma,” Blood 76:549-554, 1990.
Price et al., “Expression, purification and characterization of recombinant murine granuloc
Marshall & Gerstein & Borun LLP
Nashed Nashaat T.
Schnizer Holly
The University of Texas Systems
LandOfFree
Mutant human factor IX with an increased resistance to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant human factor IX with an increased resistance to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant human factor IX with an increased resistance to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652587